Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1/2 4Phase 3 3Phase 1 3

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Gynecologic 1Endocrine 1

Conditions

Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Breast Neoplasms 1

Interventions

Cisplatin 187Carboplatin 182Paclitaxel 177Docetaxel 145Cyclophosphamide 129Dexamethasone 117pembrolizumab 106Doxorubicin 103Bevacizumab 103Gemcitabine 102Rituximab 96Prednisone 87Fluorouracil 86Pemetrexed 82Radiotherapy 77Vincristine 71Etoposide 71Capecitabine 69Nivolumab 68Trastuzumab 67Leucovorin 64Cytarabine 57Methotrexate 52Oxaliplatin 49atezolizumab 48Lenalidomide 43Ipilimumab 40Filgrastim 40Bortezomib 39Sorafenib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Has results × Alpelisib × Clear all
NCT04729387 2026-06-04

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Novartis

Phase 3 Terminated
358 enrolled 19 charts
Gynecologic

Ovarian Neoplasms

NCT04251533 2026-05-11

EPIK-B3

Novartis

Phase 3 Terminated
137 enrolled 21 charts
Breast

Triple Negative Breast Neoplasms

NCT02437318 2025-02-13

SOLAR-1

Novartis

Phase 3 Completed
572 enrolled 22 charts 1 FDA
BreastEndocrine

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡